2-(2,2-dimethyl-propoxy)-tetrahydro-pyran | 1927-65-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 2-(2,2-dimethyl-propoxy)-tetrahydro-pyran
• 英文别名: 2-Neopentyloxy-tetrahydro-pyran；2-Neopentyloxy-tetrahydropyran；2-(2,2-Dimethylpropoxy)oxane
• CAS: 1927-65-7
• 化学式: C₁₀H₂₀O₂
• 分子量: 172.268
• InChiKey: AKCAQVJJKJHURV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2,2-dimethyl-propoxy)-tetrahydro-pyran 在 三氟甲磺酸三甲基硅酯 、 氨 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 1-O-(2,2-dimethylpropyl)-β-D-ribofuranose
  参考文献：
  名称：

  一锅四氢吡喃基（THP）醚中间体的糖基化

  摘要：

  四氢吡喃基（THP）醇的衍生物被转换在单罐和立体选择性的方式将相应的1- ø -烷基-2,3,5-三ö治疗苯甲酰基β-d-ribofuranosides与1- ö -乙酰-2,3,5-三-O-苯甲酰基-β-D-呋喃呋喃糖和三氟甲磺酸三甲基甲硅烷基酯（TMSOTf）。对1 - O-乙酰基-2,3,4,6-四-O-苄基-吡喃葡萄糖苷（α/β9：1）也应用相同的方案，通过与1 - O-甲基-2反应，得到3，4-三-O-苄基-6-THP-α-D-吡喃葡萄糖苷，相应的二糖胺（α/β3：1）。该反应收率高，并且在非常温和的条件下（-30°C）使用容易获得的起始原料快速进行。

  DOI：

  10.1016/s0040-4039(00)77285-6

文献信息

• KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES
  申请人：ESPERION THERAPEUTICS, INC.

  公开号：US20140228439A1

  公开（公告）日：2014-08-14

  The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  本发明涉及新型酮化合物、包含酮化合物的组合物以及用于治疗和预防心血管疾病、脂质代谢异常、蛋白质代谢异常和葡萄糖代谢障碍的方法，其中包括给予含有酮化合物的组合物。本发明的化合物、组合物和方法还可用于治疗和预防阿尔茨海默病、综合征X、过氧化物酶体增殖物激活受体相关疾病、败血症、血栓性疾病、肥胖症、胰腺炎、高血压、肾脏疾病、癌症、炎症和阳痿。在某些实施例中，本发明的化合物、组合物和方法可与其他治疗药物（如降胆固醇和降血糖药物）联合治疗。
• Modified alginates for cell encapsulation and cell therapy
  申请人：Massachusetts Institute of Technology

  公开号：US10285949B2

  公开（公告）日：2019-05-14

  Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.

  本文公开了共价修饰的藻酸盐聚合物，具有增强的生物相容性和定制的理化特性，以及其制造和使用方法。共价修饰的藻酸盐可用作细胞包裹和移植的基质。此外，还公开了表征改性藻酸盐聚合物的生物相容性和理化性质的高通量方法。
• Sacubitril intermediate and preparation method thereof
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US10479753B2

  公开（公告）日：2019-11-19

  The present invention relates to a sacubitril intermediate and a preparation method thereof. The sacubitril intermediate disclosed herein can be prepared by a deprotection reaction of a compound. In addition, the intermediate can be used as a raw material to synthesize sacubitril. The method disclosed herein has advantages of easily obtained raw materials, simple preparation process, low cost, environment friendly, and etc., which is very suitable for industrial production.

  本发明涉及一种sacubitril中间体及其制备方法。本发明公开的sacubitril中间体可通过化合物的脱保护反应制备。此外，该中间体还可用作合成 sacubitril 的原料。本发明公开的方法具有原料易得、制备工艺简单、成本低、环境友好等优点，非常适合工业化生产。
• Reductions with Metal Hydrides. XIV. Reduction of 2-Tetrahydropyranyl and 2-Tetrahydrofuranyl Ethers
  作者：Ernest L. Eliel、Bernard E. Nowak、Ronald A. Daignault、Victor G. Badding

  DOI：10.1021/jo01018a082

  日期：1965.7
• MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY
  申请人：Massachusetts Institute of Technology

  公开号：US20170239190A1

  公开（公告）日：2017-08-24

  Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.